Twenty-year Risk of Prostate Cancer Death by Midlife Prostate-specific Antigen and a Panel of Four Kallikrein Markers in a Large Population-based Cohort of Healthy Men

Large Population ◽

Specific Antigen ◽

Population Based ◽

Cancer Death ◽

Healthy Men ◽

436: Validation of Rising Prostate Specific Antigen as a Predictor of Prostate Cancer Death Following Treatment of Localized Prostate Cancer with Either Surgery or Radiation

The Journal of Urology ◽

10.1016/s0022-5347(18)37698-5 ◽

2004 ◽

Vol 171 (4S) ◽

pp. 115-115

Author(s):

Peter C. Albertsen ◽

James A. Hanley ◽

David F. Penson ◽

Judith Fine

Keyword(s):

Prostate Cancer ◽

Specific Antigen ◽

Localized Prostate Cancer ◽

Cancer Death ◽

Time to second prostate-specific antigen failure is a surrogate endpoint for prostate cancer death in a prospective trial of therapy for localized disease

Urology ◽

10.1016/s0090-4295(99)80423-3 ◽

1996 ◽

Vol 47 (2) ◽

pp. 236-239 ◽

Cited By ~ 34

Author(s):

Anthony L. Zietman ◽

Katherine C. Dallow ◽

Patricia A. McManus ◽

Niall M. Heney ◽

William U. Shipley

Keyword(s):

Prostate Cancer ◽

Prospective Trial ◽

Specific Antigen ◽

Surrogate Endpoint ◽

Cancer Death ◽

Prostate Cancer Death ◽

Localized Disease

Prostate-specific antigen (PSA) rate of decline post external beam radiotherapy predicts prostate cancer death

Radiotherapy and Oncology ◽

10.1016/j.radonc.2013.03.030 ◽

2013 ◽

Vol 107 (2) ◽

pp. 129-133 ◽

Cited By ~ 14

Author(s):

Zumin Shi ◽

Carole B. Pinnock ◽

Stephen Kinsey-Trotman ◽

Martin Borg ◽

Kim L. Moretti ◽

...

Keyword(s):

Prostate Cancer ◽

External Beam Radiotherapy ◽

Specific Antigen ◽

External Beam ◽

Cancer Death ◽

Prostate Cancer Death ◽

Rate Of Decline

Effect of intervention on decision making of treatment for disease progression, prostate-specific antigen biochemical failure and prostate cancer death

Health Expectations ◽

10.1111/j.1369-7625.2012.00802.x ◽

2012 ◽

Vol 17 (6) ◽

pp. 776-783 ◽

Cited By ~ 1

Author(s):

Rex C.-C. Huang ◽

Anssi Auvinen ◽

Matti Hakama ◽

Teuvo L. J. Tammela ◽

Martti Ala-Opas ◽

...

Keyword(s):

Prostate Cancer ◽

Decision Making ◽

Disease Progression ◽

Specific Antigen ◽

Biochemical Failure ◽

Cancer Death ◽

VALIDATION OF INCREASING PROSTATE SPECIFIC ANTIGEN AS A PREDICTOR OF PROSTATE CANCER DEATH AFTER TREATMENT OF LOCALIZED PROSTATE CANCER WITH SURGERY OR RADIATION

The Journal of Urology ◽

10.1097/01.ju.0000124381.93689.b4 ◽

2004 ◽

Vol 171 (6 Part 1) ◽

pp. 2221-2225 ◽

Cited By ~ 64

Author(s):

PETER C. ALBERTSEN ◽

JAMES A. HANLEY ◽

DAVID F. PENSON ◽

JUDITH FINE

Keyword(s):

Prostate Cancer ◽

Specific Antigen ◽

Localized Prostate Cancer ◽

Cancer Death ◽

Re: Melissa Assel, Anders Dahlin, David Ulmert, et al. Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening. Eur Urol 2018;73:961–7

European Urology ◽

10.1016/j.eururo.2018.10.004 ◽

2019 ◽

Vol 75 (3) ◽

pp. e54-e55

Author(s):

Kathryn L. Penney ◽

Massimo Loda ◽

Meir J. Stampfer

Keyword(s):

Prostate Cancer ◽

Lead Time ◽

Large Population ◽

Specific Antigen ◽

Population Based ◽

Prostate Specific Antigen Screening ◽

Long Term Follow Up

1013 Time to second prostate specific antigen (PSA) failure is a surrogate endpoint for prostate cancer death in prospective trials of therapy for localized disease

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/0360-3016(95)97838-r ◽

1995 ◽

Vol 32 ◽

pp. 229 ◽

Cited By ~ 1

Author(s):

A.L. Zietman ◽

K.C. Dallow ◽

W.U. Shipley ◽

N.M. Haney ◽

P.L. McManus

Keyword(s):

Prostate Cancer ◽

Specific Antigen ◽

Surrogate Endpoint ◽

Cancer Death ◽

Psa Failure ◽

Prostate Cancer Death ◽

Localized Disease ◽

Prospective Trials

Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening

European Urology ◽

10.1016/j.eururo.2017.10.004 ◽

2018 ◽

Vol 73 (6) ◽

pp. 961-967 ◽

Cited By ~ 5

Author(s):

Melissa Assel ◽

Anders Dahlin ◽

David Ulmert ◽

Anders Bergh ◽

Pär Stattin ◽

...

Keyword(s):

Prostate Cancer ◽

Lead Time ◽

Large Population ◽

Specific Antigen ◽

Population Based ◽

Prostate Specific Antigen Screening ◽

Long Term Follow Up

Reply to Kathryn L. Penney, Massimo Loda, and Meir J. Stampfer's Letter to the Editor re: Melissa Assel, Anders Dahlin, David Ulmert, et al. Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening. Eur Urol 2018;73:961–7

European Urology ◽

10.1016/j.eururo.2018.10.003 ◽

2019 ◽

Vol 75 (3) ◽

pp. e56

Author(s):

Andrew J. Vickers ◽

Hans Lilja ◽

Melissa Assel

Keyword(s):

Prostate Cancer ◽

Lead Time ◽

Large Population ◽

Specific Antigen ◽

Population Based ◽

Letter To The Editor ◽

Long Term Follow Up

Reduced cancer-specific survival of low prostate-specific antigen in high-grade prostate cancer: A population-based retrospective cohort study

International Journal of Surgery ◽

10.1016/j.ijsu.2020.02.024 ◽

2020 ◽

Vol 76 ◽

pp. 64-68 ◽

Cited By ~ 5

Author(s):

Pan Song ◽

Bo Yang ◽

Zhufeng Peng ◽

Jing Zhou ◽

Zhengju Ren ◽

...

Keyword(s):

Prostate Cancer ◽

Cohort Study ◽

Retrospective Cohort Study ◽

Retrospective Cohort ◽

Specific Antigen ◽

Population Based ◽

High Grade ◽

Cancer Specific Survival